- Home
- PHAT vs AEVA Comparison
PHAT vs AEVA Comparison
Compare PHAT & AEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHAT | AEVA |
|---|---|---|
| Founded | 2018 | 2019 |
| Country | United States | United States |
| Employees | N/A | 276 |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 819.5M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | PHAT | AEVA |
|---|---|---|
| Price | $11.56 | $14.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $19.50 | ★ $26.50 |
| AVG Volume (30 Days) | 898.5K | ★ 1.6M |
| Earning Date | 05-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.72 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $175,110,000.00 | N/A |
| Revenue This Year | $83.18 | $59.90 |
| Revenue Next Year | $61.43 | $167.01 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 216.93 | N/A |
| 52 Week Low | $2.21 | $2.52 |
| 52 Week High | $18.31 | $38.79 |
Technical Indicators
Market Signals| Indicator | PHAT | AEVA |
|---|---|---|
| Relative Strength Index (RSI) | 39.53 | 54.54 |
| Support Level | $10.65 | $12.28 |
| Resistance Level | $12.77 | $17.31 |
| Average True Range (ATR) | 0.87 | 1.10 |
| MACD | 0.09 | 0.23 |
| Stochastic Oscillator | 14.01 | 75.70 |
Price Performance
Historical ComparisonAbout PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About AEVA Aeva Technologies Inc.
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.